Taken together, amyloid pathological analysis in founder 2-linage mice showed consistent results with those from founder 1-linage mice that Trem2 H157Y reduces amyloid burden, dystrophic neurites, and gliosis at 8.5 months of age. This evidence concerns the gene TREM2 and amyloidosis.